NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Paycor HCM, Inc. (NYSE: PYCR), relating to the proposed merger with Paychex. Under the terms of the agreement, Paychex will acquire Paycor at $22.50 per share.Click here for more https://monte ...

AUSTIN, Texas, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Asure (NASDAQ: ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, announced today that serial HR and pay technology pioneer Jay Whitehead has joined to lead its AsurePay™ Platinum VIP Banking card and Marketplace businesses. Jay Whitehead founded Human Resources Outsourcing Today magazine and HRO World conferences, and led or helped lead media companies including CRN, PC Magazine, UPSIDE and Daily Journals, and HR, PEO ...

投资策略 - 投资策略侧重于长期投资 同时结合短期做空以发现超额收益机会 [2] - 投资方法采用自下而上的分析 深入研究公司的基本面优势和劣势 [2] - 投资期限为中长期 目标是识别具有坚实基本面 可持续竞争优势和增长潜力的公司 [2] Paycor HCM 投资观点 - 对Paycor HCM的投资观点是下调至持有评级 因为对其增长潜力缺乏信心 [3]

SAN DIEGO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Paycor HCM, Inc. (NASDAQ: PYCR) to determine whether certain Paycor officers and directors violated securities laws and breached fiduciary duties to shareholders. Paycor HCM, together with its subsidiaries, engages in the provision of human capital management solutions for small and medium-sized businesses primarily in the United States. What Now: If you own shares of Paycor HCM, Inc. and have lost money in ...

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by ...

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive n ...

文章核心观点 - HUTCHMED和Innovent联合宣布，其联合疗法ELUNATE®（fruquintinib）和TYVYT®（sintilimab注射液）在中国获得条件性批准，用于治疗先前系统治疗失败且不适合手术或放疗的晚期子宫内膜癌患者[1][2] 批准背景 - 该批准基于FRUSICA-1研究的注册阶段数据，该研究是一项多中心、开放标签的II期研究，评估了fruquintinib与sintilimab联合治疗在经历疾病复发、进展或对铂类双药化疗治疗不耐受的子宫内膜癌患者中的效果[2] - 研究结果显示，IRC评估的客观缓解率（ORR）为35.6%，疾病控制率（DCR）为88.5%，中位响应时间（TTR）为1.6个月，中位无进展生存期（PFS）为9.5个月，中位总生存期（OS）为21.3个月[2] 专家观点 - 复旦大学附属肿瘤医院妇科肿瘤科主任吴小华教授表示，该批准代表了管理这种具有挑战性的疾病的范式转变，创新组合不仅利用了靶向治疗和免疫治疗的协同效应，还解决了传统治疗对患者反应有限的关键差距[3] - HUTCHMED的研发和首席医学官Michael Shi博士表示，该批准代表了晚期子宫内膜癌患者长期等待更有效治疗的重大进展，并强调了fruquintinib与其他治疗药物联合使用的潜力[3] - Innovent的高级副总裁周辉博士表示，该批准标志着晚期子宫内膜癌治疗领域的重大进展，与HUTCHMED合作，旨在提供一种改善生存率和提高生活质量的新治疗选择[3] 临床试验计划 - 计划进行一项III期确证性研究，以进一步验证fruquintinib和sintilimab联合治疗在该适应症中的效果[4] 关于子宫内膜癌 - 子宫内膜癌起源于子宫，是全球健康挑战之一，2020年全球约有41.7万人被诊断为子宫内膜癌，导致约9.7万人死亡，中国约有8.2万新病例和1.7万死亡病例[6] - 尽管早期子宫内膜癌通常可以通过手术切除，但复发和/或转移性子宫内膜癌仍然是一个高度未满足需求的领域，治疗选择有限，预后较差[6] 关于Fruquintinib - Fruquintinib是一种选择性口服血管内皮生长因子（VEGF）受体抑制剂，靶向VEGFR-1、-2和-3，旨在通过限制非靶向激酶活性来实现持续的目标抑制和组合治疗的灵活性[7] - Fruquintinib在中国已获批用于治疗先前接受过氟嘧啶、奥沙利铂和伊立替康为基础的化疗的转移性结直肠癌患者，并与Eli Lilly合作开发和市场推广[8] - Fruquintinib在全球多个国家和地区获得批准，包括美国、欧盟、瑞士、加拿大、日本、英国、阿根廷、澳大利亚和新加坡，并在许多其他司法管辖区推进监管申请[9] 关于Sintilimab - Sintilimab是一种PD-1免疫球蛋白G4单克隆抗体，由Innovent和Eli Lilly合作开发，通过阻断PD-1/PD-Ligand 1（PD-L1）通路，重新激活T细胞杀死癌细胞[11] - 在中国，sintilimab已获批并纳入国家医保药品目录（NRDL），用于七种适应症，包括复发或难治性经典霍奇金淋巴瘤、不可切除的局部晚期或转移性非小细胞肺癌等[11] - 2024年12月，sintilimab与fruquintinib联合治疗晚期子宫内膜癌的第八适应症获得NMPA批准[12] 公司背景 - HUTCHMED是一家创新型商业阶段生物制药公司，致力于发现和全球开发及商业化靶向疗法和免疫疗法，用于治疗癌症和免疫性疾病，拥有约5000名员工，其中约1800名专注于肿瘤学/免疫学[15] - Innovent是一家领先的生物制药公司，成立于2011年，致力于为全球患者提供负担得起的高质量生物制药，已推出11种产品，5种新药申请正在监管审查中，3种资产处于III期或关键临床试验阶段，17种分子处于早期临床阶段[16]

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2025 will continue to include ORPATHYS® (savolitinib) at the same terms as the current two-year agreement. ORPATHYS® is an oral, potent, and highly selective MET tyro ...

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA® (fruqui ...